BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

951 related articles for article (PubMed ID: 25449802)

  • 1. Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation.
    Han X; Li Z; Sun J; Luo C; Li L; Liu Y; Du Y; Qiu S; Ai X; Wu C; Lian H; He Z
    J Control Release; 2015 Jan; 197():29-40. PubMed ID: 25449802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyaluronic acid ion-pairing nanoparticles for targeted tumor therapy.
    Li W; Yi X; Liu X; Zhang Z; Fu Y; Gong T
    J Control Release; 2016 Mar; 225():170-82. PubMed ID: 26826304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin.
    Cho HJ; Yoon IS; Yoon HY; Koo H; Jin YJ; Ko SH; Shim JS; Kim K; Kwon IC; Kim DD
    Biomaterials; 2012 Feb; 33(4):1190-200. PubMed ID: 22074664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robust PEGylated hyaluronic acid nanoparticles as the carrier of doxorubicin: mineralization and its effect on tumor targetability in vivo.
    Han HS; Lee J; Kim HR; Chae SY; Kim M; Saravanakumar G; Yoon HY; You DG; Ko H; Kim K; Kwon IC; Park JC; Park JH
    J Control Release; 2013 Jun; 168(2):105-14. PubMed ID: 23474029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transformative hyaluronic acid-based active targeting supramolecular nanoplatform improves long circulation and enhances cellular uptake in cancer therapy.
    Zhong L; Xu L; Liu Y; Li Q; Zhao D; Li Z; Zhang H; Zhang H; Kan Q; Wang Y; Sun J; He Z
    Acta Pharm Sin B; 2019 Mar; 9(2):397-409. PubMed ID: 30972285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy.
    Choi KY; Yoon HY; Kim JH; Bae SM; Park RW; Kang YM; Kim IS; Kwon IC; Choi K; Jeong SY; Kim K; Park JH
    ACS Nano; 2011 Nov; 5(11):8591-9. PubMed ID: 21967065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery.
    Park JH; Cho HJ; Yoon HY; Yoon IS; Ko SH; Shim JS; Cho JH; Park JH; Kim K; Kwon IC; Kim DD
    J Control Release; 2014 Jan; 174():98-108. PubMed ID: 24280260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo.
    Choi KY; Min KH; Yoon HY; Kim K; Park JH; Kwon IC; Choi K; Jeong SY
    Biomaterials; 2011 Mar; 32(7):1880-9. PubMed ID: 21159377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bile acid-conjugated chondroitin sulfate A-based nanoparticles for tumor-targeted anticancer drug delivery.
    Lee JY; Chung SJ; Cho HJ; Kim DD
    Eur J Pharm Biopharm; 2015 Aug; 94():532-41. PubMed ID: 26149228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of hyaluronic acid-based micelles and polyethylene glycol-based micelles on reversal of multidrug resistance and enhanced anticancer efficacy in vitro and in vivo.
    Wang J; Li Y; Wang L; Wang X; Tu P
    Drug Deliv; 2018 Nov; 25(1):330-340. PubMed ID: 29350064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyethylene glycol-conjugated chondroitin sulfate A derivative nanoparticles for tumor-targeted delivery of anticancer drugs.
    Lee JY; Park JH; Lee JJ; Lee SY; Chung SJ; Cho HJ; Kim DD
    Carbohydr Polym; 2016 Oct; 151():68-77. PubMed ID: 27474544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of a tumor microenvironment pH-responsive cleavable PEGylated hyaluronic acid nano-drug delivery system for colorectal cancer treatment.
    Zhang X; Zhao M; Cao N; Qin W; Zhao M; Wu J; Lin D
    Biomater Sci; 2020 Mar; 8(7):1885-1896. PubMed ID: 32022813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin.
    Mezghrani O; Tang Y; Ke X; Chen Y; Hu D; Tu J; Zhao L; Bourkaib N
    Int J Pharm; 2015 Jan; 478(2):553-68. PubMed ID: 25455765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
    Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
    Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyaluronic acid-decorated PLGA-PEG nanoparticles for targeted delivery of SN-38 to ovarian cancer.
    Vangara KK; Liu JL; Palakurthi S
    Anticancer Res; 2013 Jun; 33(6):2425-34. PubMed ID: 23749891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models.
    Chi Y; Yin X; Sun K; Feng S; Liu J; Chen D; Guo C; Wu Z
    J Control Release; 2017 Sep; 261():113-125. PubMed ID: 28666726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and characterization of hyaluronic acid modified PLGA based nanoparticles for improved efficacy of cisplatin in solid tumor.
    Alam N; Koul M; Mintoo MJ; Khare V; Gupta R; Rawat N; Sharma PR; Singh SK; Mondhe DM; Gupta PN
    Biomed Pharmacother; 2017 Nov; 95():856-864. PubMed ID: 28903181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction/pH dual-sensitive PEGylated hyaluronan nanoparticles for targeted doxorubicin delivery.
    Xu M; Qian J; Suo A; Wang H; Yong X; Liu X; Liu R
    Carbohydr Polym; 2013 Oct; 98(1):181-8. PubMed ID: 23987334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: In vitro and in vivo evaluation.
    Alibolandi M; Abnous K; Sadeghi F; Hosseinkhani H; Ramezani M; Hadizadeh F
    Int J Pharm; 2016 Mar; 500(1-2):162-78. PubMed ID: 26802496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.